申请人:Banyu Pharmaceutical Co., Ltd.
公开号:US06703373B1
公开(公告)日:2004-03-09
A compound represented by the formula or a pharmaceutically acceptable salt thereof
wherein R represents an unsubstituted pyridyl, furyl or thienyl group, or a pyridyl, furyl or thienyl group each of which has one or more substituents selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group except that when the pyridyl, furyl or thienyl group has a lower alkoxy group as a substituent, each of which simultaneously has another substituent selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group, m represents an integer of 1 to 3, and G represents a &bgr;-D-glucopyranosyl group, and the positions of substitution of the hydroxyl groups on the indolopyrrolocarbazole ring are the 1- and 11-positions, or the 2- and 10-positions, and an antitumore agent containing it as an effective ingredient.
The compounds have a better antitumor action than known compounds having a similar structure.
化合物的化学式为或其药学上可接受的盐,其中R代表未取代的吡啶基,呋喃基或噻吩基,或者是带有一个或多个取代基的吡啶基,呋喃基或噻吩基,所述取代基选自羟基,较低的烷氧基,羟基较低的烷基基团和羟基较低的烯基基团的群,但是当吡啶基,呋喃基或噻吩基带有较低的烷氧基取代基时,每个取代基同时具有羟基,较低的烷氧基,羟基较低的烷基基团和羟基较低的烯基基团中的另一个取代基时,m表示1到3的整数,G表示β-D-葡萄糖吡喃糖基,并且羟基取代在吲哚吡咯喹啉环上的位置为1-和11-位置,或2-和10-位置,以及含有其作为有效成分的抗肿瘤剂。这些化合物比具有类似结构的已知化合物具有更好的抗肿瘤作用。